Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), announced today the appointment of David McIntyre as Chief Financial Officer. The company, which is advancing its lead product IkT-001 for PAH, heralds Mr. McIntyre’s two decades of experience in the life sciences sector as a valuable asset for its future endeavors. According to InvestingPro data, IKT maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 26.37, indicating robust liquidity to support its development programs.
Mr. McIntyre’s career includes C-suite roles at several biotech and medical device companies, such as Anthos Therapeutics and HeartWare International. His expertise extends to corporate governance and financial strategy, with previous senior positions at multinational corporations like Rio Tinto. Additionally, he has practiced as a senior attorney specializing in mergers, acquisitions, and corporate law. The appointment comes as IKT’s stock has shown significant momentum, with InvestingPro reporting a 23.21% return over the past week and a 30.19% gain over the last six months.
Mark Iwicki, CEO of Inhibikase, expressed confidence in leveraging McIntyre’s proficiency to propel the company’s progress. McIntyre’s academic credentials include a Bachelor of Economics (Accounting), a Bachelor of Laws, and an MBA from Duke University’s Fuqua School of Business, where he was a Fuqua Scholar.
Inhibikase’s primary focus is the development of kinase inhibitor therapeutics, with IkT-001, a prodrug of imatinib mesylate, leading its cardiopulmonary disease portfolio. The company is headquartered in Atlanta, Georgia, with additional offices in Lexington, Massachusetts.
The press release also includes forward-looking statements regarding the company’s intentions and expectations for the progression of IkT-001 and Mr. McIntyre’s anticipated contribution to its operations. However, such statements are subject to risks and uncertainties that could affect the company’s actual results.
This news is based on a press release statement and does not endorse any claims made by Inhibikase Therapeutics. The company is currently preparing to commence a Phase 2b ’702’ trial to evaluate IkT-001 as a treatment for PAH, with further details available in its periodic reports filed with the U.S. Securities and Exchange Commission. With the next earnings report due on May 15, 2025, investors seeking deeper insights into IKT’s financial health and growth prospects can access comprehensive analysis through InvestingPro’s detailed research reports, which include additional ProTips and advanced metrics for informed decision-making.
In other recent news, Inhibikase Therapeutics has made significant strides in its lead program, IkT-001Pro, designed for pulmonary arterial hypertension (PAH). The company received IND-clearance from the FDA for the Phase 2b 702 trial of IkT-001Pro, a prodrug of imatinib, marking an important step in its clinical development. Additionally, Inhibikase is pursuing Orphan Drug Designation for IkT-001Pro in PAH, following the completion of pre-clinical studies. H.C. Wainwright has maintained a Neutral rating on Inhibikase, reflecting the company’s ongoing progress with IkT-001Pro.
The company has also strengthened its leadership team by appointing Dr. Chris Cabell as President and Head of Research & Development and Dr. John Adams as Chief Scientific Officer. These appointments aim to advance the PAH treatment through upcoming clinical trials. Furthermore, Inhibikase has halted the development of its Parkinson’s disease drug, risvodetinib, after a Phase 2 trial showed limited efficacy, allowing the company to focus resources on IkT-001Pro. The company is exploring strategic options for the risvodetinib program, despite some promising secondary endpoints in the trial. These developments underscore Inhibikase’s commitment to advancing its PAH treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.